Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 12/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355699 | 0.90 | GAA (0.54) | GAAKLKB1DGAT1 | |
| SCHEMBL15049569 | 0.89 | GAA (0.59) | GAAKLKB1DGAT1 | |
| SCHEMBL20521837 | 0.89 | GAA (0.53) | GAAKLKB1DGAT1 | |
| SCHEMBL7980023 | 0.87 | KLKB1 (0.60) | GAAKLKB1DGAT1 | |
| SCHEMBL3356363 | 0.87 | GAA (0.51) | GAAKLKB1DGAT1 | |
| SCHEMBL1049941 | 0.86 | GAA (0.56) | GAAKLKB1DGAT1 | |
| SCHEMBL30730181 | 0.84 | DGAT1 (0.55) | KLKB1DGAT1KMT2A | |
| SCHEMBL14150628 | 0.84 | KLKB1 (0.48) | GAAKLKB1DGAT1 | |
| SCHEMBL1048741 | 0.84 | KLKB1 (0.48) | GAAKLKB1DGAT1 | |
| SCHEMBL25205458 | 0.82 | KMT2A (0.55) | KMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3887371-B1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| EP-3887371-B1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| CN-110475777-B | Novel pyrido [2,3-b ] indole compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2021-10-07 | — | — | US | disclosed |
| CN-113166144-A | Aryl compounds for the treatment and prevention of bacterial infections | 豪夫迈·罗氏有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3601282-B1 | NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | HOFFMANN LA ROCHE (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| CN-102216285-A | Tetrasubstituted pyridazine hedgehog pathway antagonists | LILLY CO ELI | 2011-10-12 | — | — | CN | disclosed |
| EP-2358698-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | Eli Lilly and Company (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-06-10 | — | — | US | disclosed |
| WO-2010056588-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056588-A1 | TETRASUBSTITUTED PYRIDAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2181110-A2 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2010-05-05 | — | — | EP | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
| WO-2009010455-A2 | PYRAZOLE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339603-A1 | Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection | IDO1, IDO2, TDO2 | GAA 4762/4885KLKB1 1157/4885DGAT1 4555/4885 |
| US-20100144756-A1 | NOVEL HETEROAROMATIC DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM4, GRM2 | GAA 3141/4885KLKB1 4684/4885DGAT1 3482/4885 |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | GAA 1904/4885KLKB1 1387/4885DGAT1 137/4885 |
| US-20210309658-A1 | ARYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION | CFTR, QDPR, FPR1 | GAA 2154/4885KLKB1 2474/4885DGAT1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.